Sam Daneshvari, MD
Nephrology · Glendale, CANPI 1851496145
Payments from drug & device makers
Across 478 payments — averaging $2353.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$898K
- Akebia Therapeutics Inc$171K
- Merck$40K
- Alnylam Pharmaceuticals Inc.$11K
- AstraZeneca$1K
- Amgen$915
- plus $4K from 23 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 83 | $898,017 |
| Akebia Therapeutics Inc | 146 | $170,616 |
| Merck | 2 | $39,867 |
| Alnylam Pharmaceuticals Inc. | 2 | $10,598 |
| AstraZeneca(2 entities) | 66 | $1,332 |
| Amgen(2 entities) | 39 | $915 |
| Otsuka America Pharmaceutical, Inc. | 31 | $567 |
| Mallinckrodt Hospital Products Inc. | 15 | $412 |
| Aurinia Pharma U.S., Inc. | 11 | $400 |
| GSK | 11 | $281 |
| Bayer | 9 | $267 |
| Vifor Pharma, Inc. | 11 | $228 |
| Fresenius USA Marketing, Inc. | 10 | $161 |
| Nuwellis, Inc. | 2 | $158 |
| Travere Therapeutics, Inc. | 2 | $143 |
| Johnson & Johnson | 2 | $139 |
| Novartis | 6 | $121 |
| Novo Nordisk | 6 | $119 |
| OPKO Pharmaceuticals, LLC | 7 | $110 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $100 |
| Boehringer Ingelheim | 4 | $81 |
| AbbVie(2 entities) | 3 | $69 |
| Mallinckrodt Enterprises LLC | 2 | $45 |
| Sanofi | 2 | $28 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $23 |
| ANI Pharmaceuticals, Inc. | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Calliditas Therapeutics US Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $12 |
How this compares
$1,124,859 in reported general payments places this provider in the 95th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Glendale
- Raffi MinasianGlendale$1.5M
- Artashes PatrikyanGlendale$950K
- Anjay RastogiLos Angeles$6.3M
- Aamir JamalSan Dimas$5.5M
- Mohamed El-ShahawyLos Angeles$4.4M
- Kalpesh PatelCalabasas$3.6M
- Jehad HaggiagiMission Hills$3.6M
- Malvin YanSouth Gate$3.3M
- Sohan DuaNorthridge$3.2M
- Richard LafayetteStanford$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.